ConductScience.org, home

Paper6772097

Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds.

Wise R and 2 others. Antimicrob Agents Chemother, 1980. Cited by 112 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Papers, record 6772097. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6772097

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1980
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
112
iCite
Relative citation ratio, by iCite
6.63
iCite
Revised in PubMed
2021-05-26
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wise RR
2Andrews JMJ M
3Bedford KAK A

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BacteriaMajor topic
CephalosporinsMajor topic
Anti-Bacterial Agents
Bacteroides fragilis
Ceftazidime
Enterobacteriaceae
Microbial Sensitivity Tests
Pseudomonas aeruginosa

Source PubMed

References6

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1101,128beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.Antimicrob Agents Chemother1978https://conductscience.org/library/papers/101128PubMed
2253,572HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.Antimicrob Agents Chemother1978https://conductscience.org/library/papers/253572PubMed
3314,774Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.Antimicrob Agents Chemother1979https://conductscience.org/library/papers/314774PubMed
4507,788LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.Antimicrob Agents Chemother1979https://conductscience.org/library/papers/507788PubMed
56,994,642GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.Antimicrob Agents Chemother1980https://conductscience.org/library/papers/6994642PubMed
64,208,895Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.Antimicrob Agents Chemother1972https://conductscience.org/library/papers/4208895PubMed

Cited by30

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 112 citations.

PMIDTitleJournalYearIn PapersSource
35,401,470The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.Front Microbiol2022https://conductscience.org/library/papers/35401470PubMed
29,110,143Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.Infection2018https://conductscience.org/library/papers/29110143PubMed
10,390,248Altered pharmacokinetics of ceftazidime in critically ill patients.Antimicrob Agents Chemother1999https://conductscience.org/library/papers/10390248PubMed
9,021,183In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/9021183PubMed
8,239,592Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8239592PubMed
7,030,200Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/7030200PubMed
7,023,381Activity of ceftazidime (GR 20263) against nosocomially important pathogens.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/7023381PubMed
6,972,728Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6972728PubMed
6,818,153[N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].Infection1982https://conductscience.org/library/papers/6818153PubMed
6,436,021In vitro activity of ciprofloxacin, azthreonam and ceftazidime against Serratia marcescens and Pseudomonas aeruginosa.Eur J Clin Microbiol1984https://conductscience.org/library/papers/6436021PubMed
6,357,068Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.Antimicrob Agents Chemother1983https://conductscience.org/library/papers/6357068PubMed
6,354,685Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs1983https://conductscience.org/library/papers/6354685PubMed
6,339,418Therapeutic and kinetic properties of ceftazidime in animals.Infection1983https://conductscience.org/library/papers/6339418PubMed
6,339,416Criteria for the assessment of susceptibility to ceftazidime using the disc diffusion procedure.Infection1983https://conductscience.org/library/papers/6339416PubMed
6,303,743Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.Drugs1983https://conductscience.org/library/papers/6303743PubMed
6,299,967The in vitro activity of ceftazidime against resistant clinical isolates.Infection1983https://conductscience.org/library/papers/6299967PubMed
6,297,384Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.Antimicrob Agents Chemother1982https://conductscience.org/library/papers/6297384PubMed
6,275,776Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.Antimicrob Agents Chemother1981https://conductscience.org/library/papers/6275776PubMed
3,890,729In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin.Antimicrob Agents Chemother1985https://conductscience.org/library/papers/3890729PubMed
3,884,319Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs1985https://conductscience.org/library/papers/3884319PubMed

See all 30 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6772097

GET https://conductscience.org/api/papers/v1/6772097/cited_by?page=2